Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Mitiperstat by AstraZeneca for Diastolic Heart Failure (HFpEF): Likelihood of Approval
Mitiperstat is under clinical development by AstraZeneca and currently in Phase III for Diastolic Heart Failure (HFpEF). According to GlobalData,...
Mitiperstat by AstraZeneca for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Mitiperstat is under clinical development by AstraZeneca and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Mitiperstat?
Mitiperstat is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Diastolic Heart Failure (HFpEF). According...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Mitiperstat?
Mitiperstat is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Diastolic Heart Failure (HFpEF). According...